Collegium Pharmaceutical (COLL) Capital Expenditures (2015 - 2026)

Collegium Pharmaceutical has reported Capital Expenditures for 12 years, with the latest figure at $496000.0 in Q2 2026.

• On a quarterly basis, Capital Expenditures rose 663.08% year-over-year to $496000.0 in Q2 2026; TTM through Jun 2026 was $1.6 million, a 2.03% decrease from a year earlier, with the FY2025 full-year figure at $1.7 million, up 5.33% from the prior year.
• Capital Expenditures was $496000.0 for Q2 2026 at Collegium Pharmaceutical, up from $270000.0 in the prior quarter.
• The five-year high for Capital Expenditures was $940000.0 in Q4 2022, with the low at $56000.0 in Q2 2023.
• Average Capital Expenditures over 5 years is $346722.2, with a median of $257000.0 recorded in 2024.
• The sharpest annual moves came in 2023 and 2026: Capital Expenditures sank 87.85% in 2023, then soared 663.08% in 2026.
• Over 5 years, Capital Expenditures stood at $940000.0 in 2022, then plunged by 82.55% to $164000.0 in 2023, then jumped by 247.56% to $570000.0 in 2024, then grew by 20.88% to $689000.0 in 2025, then fell by 28.01% to $496000.0 in 2026.
• The last three Capital Expenditures figures came in at $496000.0 (Q2 2026), $270000.0 (Q1 2026), and $689000.0 (Q4 2025), per Business Quant data.